

IAP10 Rec'd PCT/PTO 30 NOV 2005

Docket No.: 478-1072
Date: November 28, 2005

COMMISSIONER FOR PATENTS
P.O Box 1450
Alexandria, VA 22313-1450



In re application of: John N. STANIFORTH, et al.
Serial No.: 10/552,231
Filed: October 6, 2005
For: PHARMACEUTICAL COMPOSITIONS COMPRISING APOMORPHINE FOR PULMONARY INHALATION

Sir:

Transmitted herewith is an **Information Disclosure Statement** in the above-identified application.

- Small entity status of this application under 37 C.F.R. 1.9 and 1.27 has been established by a verified statement previously submitted.
- A verified statement to establish small entity status under 37 C.F.R. 1.9 and 1.27 is enclosed.
- No fee for additional claims is required.

- Also transmitted herewith are:
 - Petition for extension under 37 C.F.R. 1.136 (in duplicate)
 - Other: Form PTO-1449 (7 pages);
 - Complete set of references cited;
 - Appendix A, includes International Search Report issued in International Application No. PCT/GB2004/001627; and
 - Return Postcard.

- Check(s) in the amount of \$. 00 is/are attached to cover:
 - Filing fee for additional claims under 37 C.F.R. 1.16
 - Petition fee for extension under 37 C.F.R. 1.136
 - Other:

- The Assistant Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 50-0552.
 - Any filing fee under 37 C.F.R. 1.16 for the presentation of additional claims which are not paid by check submitted herewith.
 - Any patent application processing fees under 37 C.F.R. 1.17.
 - Any petition fees for extension under 37 C.F.R. 1.136 which are not paid by check submitted herewith; and it is hereby requested that this be a petition for an automatic extension of time under 37 CFR 1.136.

Cary S. Kappel, Reg. No. 36,561
DAVIDSON, DAVIDSON & KAPPEL, LLC
485 Seventh Avenue, 14th Floor
New York, New York 10018
Tel: (212) 736-1940
Fax: (212) 736-2427

UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner: To be assigned Art Unit: To be assigned
 Re: Application of: John N. STANIFORTH, et al.
 Serial No.: 10/552,231
 Filed: October 6, 2005
 For: **PHARMACEUTICAL
COMPOSITIONS COMPRISING
APOMORPHINE FOR
PULMONARY INHALATION**

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.56**

Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

November 28, 2005

Sir:

In accordance with the provisions of 37 C.F.R. § 1.97, Applicants hereby make of record the documents listed on the accompanying Form PTO-1449 (7 sheets) for consideration by the Examiner in connection with the above-identified patent application.

In accordance with 37 C.F.R. § 1.98(a)(2), copies of non-patent publications and foreign patents are enclosed. If it is determined that any of these references are not enclosed, the Examiner is requested to contact the undersigned so that a missing copy can be provided.

Pursuant to the waiver of the requirement under 37 C.F.R. § 1.98(a)(2)(ii), copies of the cited U.S. patents and applications are not enclosed.

The Examiner's attention is directed to references "GH", "GI" and "GL" on sheet 7 of the enclosed Form PTO-1449. These references were cited in the International

Search Report issued in International Application No. PCT/GB2004/001627, a copy of the Search Report is enclosed as Appendix A.

Applicants also respectfully advise the Examiner of the following co-pending U.S. patent applications which are commonly assigned to the owners of the instant application:


U.S. Patent Application Serial No. 10/413,022, entitled "Composition, Device, and Method for Treating Sexual Dysfunction Via Inhalation," filed April 14, 2003; and

U.S. Patent Application Serial No. 10/621,964, entitled "Composition, Device and Method for Treating Sexual Dysfunction Via Inhalation," filed July 17, 2003.

It is respectfully requested that the references cited in the accompanying Form PTO-1449 (7 sheets) be considered and made of record.

This Information Disclosure Statement is filed under 37 C.F.R. §1.97 (b), before the mailing of a first Office Action on the merits. Accordingly, it is believed that no fee is due. In the event any additional fee is due or any overpayment made in connection with the filing of this Information Disclosure Statement, the Commissioner is hereby authorized to charge said deficiency or credit overpayment to our Deposit Account No. 50-0552.

Respectfully submitted,
DAVIDSON, DAVIDSON & KAPPEL, LLC

By: 
Cary S. Kappel
Reg. No. 36,561

DAVIDSON, DAVIDSON & KAPPEL, LLC
485 Seventh Avenue, 14th Floor
New York, New York 10018
(212) 736-1940

--FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO.: 478.1072		SERIAL NO.: 10/552,231		
		LIST OF PRIOR ART CITED BY APPLICANT <i>NOV 30 2005</i> (Use several sheets if necessary)							APPLICANT(S): John STANIFORTH et al.				
									FILING DATE: October 6, 2005		GROUP: To be assigned		
U.S. PATENT DOCUMENTS													
*EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	AA	4	5	2	1	4	2	1	06/04/85	Foreman	514	267	09/26/83
	AB	4	6	8	7	7	7	3	08/18/87	Neumeyer, et al.	514	280	05/31/85
	AC	5	2	9	2	5	2	0	03/08/94	de Haan, et al.	424	465	08/31/92
	AD	5	4	4	1	7	4	7	08/15/95	de Haan, et al.	424	465	02/09/94
	AE	5	7	5	6	4	8	3	05/26/98	Merkus	514	58	
	AF	5	7	7	0	6	0	6	06/23/98	EI-Rashidy, et al.	514	284	10/20/95
	AG	5	9	4	5	1	1	7	08/31/99	EI-Rashidy, et al.	424	430	01/30/98
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
												YES	NO
	AH	9	4	2	2	4	4	5	10/13/94	WO (A2)	A61K	31/48	
	AI												
	AJ												
	AK												
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
	AL	Padma-Nathan, "Oral Drug Therapy for Female Sexual Dysfunction", Intl J of Impotence Research, Vol 12 Supp 3 (2000) pp S56 -S57											
	AM	Alexander-Williams, et al., "Novel routes of opioid administration," Brit. J. Anaesth., 1998; 81:3-7											
	AN	van Laar, et al., "Future delivery systems for apomorphine in patients with Parkinson's disease," Parkinson's Disease: Advances in Neurology, Lippincott Williams & Wilkins, Philadelphia, 1999; 80: 535-544.											
	AO	Goldstein, et al., "Vasculogenic female sexual dysfunction: vaginal engorgement and clitoral erectile insufficiency syndromes," Int J Impotence Res, 1998; 10(Suppl. 2) S84-S90.											
	AP	Chustecka, "New treatments for erectile dysfunction", Scrip Reports, PJB Publications Limited, (1998).											
	AQ	Gower et al., "Antagonism of Drug-induced Yawning and Penile Erections in Rats", European J of Pharmac, Vol 122 (1986) pp 239-244											
EXAMINER									DATE CONSIDERED				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO.: 478.1072		SERIAL NO.: 10/552,231			
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)									APPLICANT(S): John STANIFORTH, et al.					
									FILING DATE: October 6, 2005		GROUP: To be assigned			
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	BA	5	9	8	5	8	8	9	11/16/99	EI-Rashidy, et al.	514	284	06/22/98	
	BB	5	9	9	4	3	6	3	11/30/99	EI-Rashidy, et al.	514	284	08/24/98	
	BC	6	1	2	1	2	7	6	09/19/00	EI-Rashidy, et al.	514	284	06/22/98	
	BD	6	1	9	3	9	9	2	02/27/01	EI-Rashidy, et al.	424	430	07/02/99	
	BE	6	2	0	0	5	9	1	03/13/01	Hussain, et al.	424	434	12/10/98	
	BF	6	2	0	0	9	8	3	03/13/01	EI-Rashidy, et al.	514	284	11/15/99	
	BG	6	2	9	1	4	7	1	09/18/01	Kling, et al.	514	284	12/17/98	
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	BH	9	9	0	9	8	2	8	03/04/99	WO (A1)	A01N	43/42		
	BI													
	BJ													
	BK													
	BL													
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
	BM	Uprima: Scientific Discussion re: Apomorphine in treatment of erectile dysfunction, Abbott Laboratories Ltd. (2001).												
	BN	Summary of Product Characteristics of Apomorphine 2mg and 3 mg sublingual tablets, Abbott Laboratories Ltd. (2001).												
	BO	Heaton et al., "The Characterization of a Bio-Assay of Erectile Function in a Rat Model", J of Urology, Vol 145 (1991) pp 1099-1102												
	BP	Heaton et al., "A Therapeutic Taxonomy of Treatments for Erectile Dysfunction: An Evolutionary Imperative", Intl J of Impotence Research, Vol 9 (1997) pp 115-121												
	BQ	Segraves et al., "Effects of Psychotropic Drugs on Human Erection and Ejaculation", Arch Gen Psychiatry, Vol 46 (1989)												
EXAMINER										DATE CONSIDERED				
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO.: 478.1072	SERIAL NO.: 10/552,231
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT(S): John N. STANIFORTH, et al.								
		FILING DATE: October 6, 2005							GROUP: To be assigned	

U.S. PATENT DOCUMENTS

*EXAMINE R INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	CA	6	3	0	6	4	3	7	10/23/01	El-Rashidy, et al.	424	464	06/29/00
	CB	6	3	4	2	2	5	1	01/29/02	Illum, et al.	424	501	06/02/00
	CC	6	3	9	5	7	4	4	05/28/02	Adams, et al.	514	284	06/18/99
	CD	6	4	3	6	9	5	0	08/20/02	Achari, et al.	514	284	06/16/99
	CE	6	5	1	4	4	8	2	02/04/03	Bartus, et al.	514	220	09/19/00
	CF	6	5	6	6	3	6	8	05/20/03	El-Rashidy, et al.	514	284	10/23/01
	CG	6	5	2	8	5	2	1	03/04/03	Ruff, et al.	514	284	11/14/01

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES NO	
	CH	9	9	2	7	9	0	5	06/10/99	WO(A1)	A61K	9/00		
	CI	9	9	3	8	4	6	7	08/05/99	WO(A1)	A61F	6/06		
	CJ	9	9	6	6	9	0	9	12/29/99	WO (A2)	A61K	31/00		
	CK	9	9	6	6	9	3	3	12/29/99	WO (A1)	A61K	31/505		
	CL	0	0	3	5	4	5	7	06/22/00	WO (A1)	A61K	31/485		
	CM	9	5	2	8	9	3	0	11/02/95	WO (A1)	A61K	31/485		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	CN	Laduron et al., "Domperidone, a Specific In Vitro Dopamine Antagonist, Devoid of In Vivo Central Dopaminergic Activity", Biochem Pharmac., Vol 28 (1979) pp 2161-2165
	CO	Bladessarini et al., "Preclinical Studies of the Pharmacology of Aporphines", Basic Pharmac., Vol 1 (1981)
	CP	Lal et al., "Effect of Domperidone on Apomorphine-Induced Growth Hormone Secretion in Normal Men", J of Neurotransmission, Vol 54 (1982) pp 75-84
	CQ	Heaton, "Neural and Pharmacological Determinants of Erection", Intl j of Impotence Research, Vol 10 Supp 2 (1998) pp S34-S39
	CR	Gancher et al., "Peripheral Pharmacokinetics of Apomorphine in Humans", Annals of Neurology, Vol 26 (1989)
	CS	Heaton et al., "Recovery of Erectile Function by the Oral Administration of Apomorphine", Urology, Vol 45 No 2 (1995)
	CT	Sachs et al., "Effects of Copulation on Apomorphine-Induced Erection in Rats", Pharmcaol Biochem & Behavior, Vol 48 No 2 (1994) pp 423-428
	CU	"Oral Medication for Impotence", TLC Pharmacy Men's Newsletter, Issue 2; (downloaded from the internet at http://lcparmacy.com/mends_newsletter_2.html on Nov. 15, 1998)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO.: 478.1072		SERIAL NO.: 10/552,231			
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)										APPLICANT(S):John N. STANIFORTH, et al.				
										FILING DATE: October 6, 2005		GROUP: To be assigned		
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	DA	5	7	7	0	6	0	6	06/23/98	EI-Rashidy	514	284		
	DB	4	0	8	0	4	5	6	03/21/78	Seidelmann, et al.	424	258		
	DC	6	4	0	3	6	0	5	06/11/02	Heaton, et al.	514	284		
	DD													
	DE													
	DF													
	DG													
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	DH	0	0	7	6	5	0	9 -	12/21/00	WO(A1)	A61K	31/44		
	DI	0	1	7	4	3	5	8	10/11/01	WO(A1)	A61K	31/4375		
	DJ	0	1	7	6	6	0	2	10/18/01	WO (A1)	A61K	31/473		
	DK	0	1	8	2	9	0	6	11/08/01	WO(A1)	A61K	9/72		
	DL													
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
	DM	Moyer, Female Sexual Dysfunction, Urch Publishing (August 1998)												
	DN	Lal, et al., "Apomorphine in the Evaluation of Dopaminergic Function in Man," Prog. Neuro-Psychopharmacol. & Biol. Psychiat. vol 12, pp. 117-164 (1988)												
	DO	Harvard Scientific (Harvard Scientific Corp., "Harvard Scientific Acquires Rights to Oral Treatment for Both Male and Female Sexual Dysfunction, pp. 1-3, (Jun. 12, 1998)												
	DP	New Perspectives in Management of Female Sexual Dysfunction: Agenda for Oct. 23-25, 1998 conference in Maine												
	DQ	Essink, et al., "Selective and Quantitative Isolation and Determination of Apomorphine in Human Plasma", J of Chromatography, Vol 570 (1991) pp 419-424												
	DR	Gancher et al., "Absorption of Apomorphine by Various Routes in Parkinsonism", Movement Disorders, Vol 6 No 3 (1991) pp 212-216												
	DS	Lal et al., "Effect of Bromocriptine in Patients with Apomorphine-Responsive Erectile Impotence: An Open Study", J Psychiatr Neurosci, Vol 16 No 5 (1991)												
EXAMINER														

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO.: 478.1072		SERIAL NO.: 10/552,231				
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)									APPLICANT(S): John N. STANIFORTH, et al.						
									FILING DATE: October 6, 2005		GROUP: To be assigned				
U.S. PATENT DOCUMENTS															
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
	EA														
FOREIGN PATENT DOCUMENTS															
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
		EB	0	2	2	4	2	0	2	03/28/02	WO(A1)	A61K	31/44	YES	NO
		EC	0	2	3	9	8	7	9	05/23/02	WO (A2)	A61B			
		ED	2	0	02	02	42	0	2	03/28/02	WO(A1)	A61K			
		EE	1	9	99	06	69	0	9	12/29/99	WO(A2)	A61K			
		EF	0	4	7	5	4	8	2	03/18/92	EP	A61K	47/02		
		EG	0	6	8	9	4	3	8	01/03/96	EP	A61K	31/485		
		EH	1	2	2	4	9	3	3	07/24/02	EP	A61K	31/505		
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)															
	EI	Fourcroy, "Issues and Priorities in the Development of Drug Treatments for Female Sexual Dysfunction", International J. Of Impotence Research, 10 Supp 2 (1998)													
	EJ	Fernandez-Guasti et al., "Separation of Dopaminergic and Serotonergic Inhibitory Mechanisms in the mediation of Estrogen-Induced Lordosis Behavior in the Rat", Pharm. Biochem. & Behavior, Vol 27 pp 93-98													
	EK	Heaton et al., "Effects of Castration and Exogenous Testosterone Supplementation in an Animal Model of Penile Erection", J of Urology, Vol 151 (1994) pp 797-800													
	EL	Goodman & Gilman, Pharmacological Basis of Therapeutics, 9 th Ed. pp 1-9													
	EM	Pehek et al., "Apomorphine and Haloperidol, but not Domperidone, Affect Penile Reflexes in Rats", Pharm Biochem & Behavior, Vol 31 (1998) pp 201-208													
	EN	Danjou et al., "Assessment of Erectogenic Properties of Apomorphine and Yohimbine in Man", Br J clin Pharmac, Vol 26 (1988) 733-739													
	EO	Tagliamonte et al., "Possible Stimulatory Role of Brain Dopamine in the Copulatory Behavior of Male Rats", Pharmac Biochem and Behavior, Vol 2 (1974) pp 257-260													
EXAMINER								DATE CONSIDERED							
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>															

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO.: 478.1072		SERIAL NO.: 10/552,231		
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)									APPLICANT(S): John N. STANIFORTH, et al.				
									FILING DATE: October 6, 2005		GROUP: To be assigned		
U.S. PATENT DOCUMENTS													
*EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
FA	20	02	01	65	1	2	2	11/07/02	Heaton et al.	514	1	05/02/02	
FB	20	02	01	65	2	4	9	11/07/02	Achari et al.	514	289	01/31/02	
FC	20	02	01	93	3	9	7	12/19/02	Achari et al.	514	295	01/31/02	
FD	20	02	01	93	4	4	2	12/19/02	Heaton et al.	514	579	04/22/02	
FE	20	03	00	17	1	1	5	01/25/03	Rabinowitz et al.	424	46	05/15/02	
FF	20	02	00	35	9	9	3	03/28/02	Edwards et al.	128	203.15	06/08/01	
FG	20	02	00	02	1	7	5	01/03/02	Behl et al.	514	282	11/06/01	
FH	20	02	00	02	1	7	6	01/03/02	Gupta et al.	514	284	03/29/01	
FI	20	02	01	65	1	2	2	11/07/02	Heaton et al.	514	1	05/02/02	
FJ	20	02	00	35	1	3	1	03/21/02	El-Rashidy et al.	514	321	10/03/01	
FK	20	02	00	86	8	7	6	07/04/02	Ruff et al.	514	295	10/10/01	
FL	20	02	01	27	1	8	8	09/12/02	Platz et al.	424	46	02/01/02	
FM	20	02	01	61	0	1	7	10/31/02	Achari et al.	514	289	01/31/02	
FN	20	03	00	91	5	1	2	05/15/03	Adjei et al.	424	46	09/03/02	
FO	20	02	00	6	9	3	3	01/17/02	Gupta et al.	514	295	03/14/01	
FP	20	03	00	92	7	2	5	05/15/03	Heaton et al.	514	288	05/20/02	
FQ	20	02	01	15	6	8	3	08/22/02	Ruff et al.	514	295	11/14/01	
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
												YES	NO
	FR												
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
	FS												
EXAMINER									DATE CONSIDERED				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

--FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE								ATTY. DOCKET NO.: 478.1072		SERIAL NO.: 10/552,231			
LIST OF PRIOR ART CITED BY APPLICANT <small>(Use several sheets if necessary)</small>										APPLICANT(S): John STANIFORTH et al.					
										FILING DATE: October 6, 2005					
U.S. PATENT DOCUMENTS															
*EXAMINER INITIAL		DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	GA	20	04	02	04	4	3	9	10/14/04	STANIFORTH, et al.	514	295			
	GB	20	04	02	04	4	4	0	10/14/04	STANIFORTH, et al.	514	295			
	GC														
	GD														
	GE														
	GF														
	GG														
FOREIGN PATENT DOCUMENTS															
		DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO	
	GH	01	0	7	4	3	5	8	10/11/01	WO					
	GI	03	0	2	6	6	3	1	04/03/03	WO					
	GJ	00	0	2	7	3	6	3	05/18/00	WO					
	GK														
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)															
	GL	"Inhaled Apomorphine Promising for Erectile Dysfunction Treatment," Pharmaceutical Journal; 09 August 03; United Kingdom; Vol. 271, no. 7261, p. 170													
	GM														
	GN														
	GO														
	GP														
	GQ														
EXAMINER										DATE CONSIDERED					
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>															